Evaluation of pragmatic oxygenation measurement as a proxy for Covid-19 severity.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
15 11 2023
15 11 2023
Historique:
received:
23
05
2023
accepted:
04
10
2023
medline:
17
11
2023
pubmed:
16
11
2023
entrez:
15
11
2023
Statut:
epublish
Résumé
Choosing optimal outcome measures maximizes statistical power, accelerates discovery and improves reliability in early-phase trials. We devised and evaluated a modification to a pragmatic measure of oxygenation function, the [Formula: see text] ratio. Because of the ceiling effect in oxyhaemoglobin saturation, [Formula: see text] ratio ceases to reflect pulmonary oxygenation function at high [Formula: see text] values. We found that the correlation of [Formula: see text] with the reference standard ([Formula: see text]/[Formula: see text] ratio) improves substantially when excluding [Formula: see text] and refer to this measure as [Formula: see text]. Using observational data from 39,765 hospitalised COVID-19 patients, we demonstrate that [Formula: see text] is predictive of mortality, and compare the sample sizes required for trials using four different outcome measures. We show that a significant difference in outcome could be detected with the smallest sample size using [Formula: see text]. We demonstrate that [Formula: see text] is an effective intermediate outcome measure in COVID-19. It is a non-invasive measurement, representative of disease severity and provides greater statistical power.
Identifiants
pubmed: 37968269
doi: 10.1038/s41467-023-42205-6
pii: 10.1038/s41467-023-42205-6
pmc: PMC10651917
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7374Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19025
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s).
Références
PLoS One. 2018 Jul 31;13(7):e0201632
pubmed: 30063769
Clin Trials. 2020 Oct;17(5):472-482
pubmed: 32674594
Lancet. 2020 Oct 10;396(10257):1071-1078
pubmed: 32987008
N Engl J Med. 2020 Nov 19;383(21):2030-2040
pubmed: 33031652
Chest. 2016 Aug;150(2):307-13
pubmed: 26836924
Intensive Care Med. 2012 Oct;38(10):1573-82
pubmed: 22926653
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
Crit Care Med. 2017 Aug;45(8):1317-1324
pubmed: 28538439
Oncologist. 2022 Apr 5;27(4):266-271
pubmed: 35380717
Lancet. 2022 Jul 30;400(10349):359-368
pubmed: 35908569
Antimicrob Agents Chemother. 2020 Aug 20;64(9):
pubmed: 32661006
J Clin Epidemiol. 2007 Dec;60(12):1234-8
pubmed: 17998077
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Rev Bras Ter Intensiva. 2022 Jan-Mar;34(1):185-196
pubmed: 35674526
Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
Epidemiol Rev. 2002;24(1):39-53
pubmed: 12119854
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Intensive Care Med Exp. 2019 Aug 20;7(1):49
pubmed: 31428882
Thorax. 2023 Oct;78(10):990-1003
pubmed: 37495364
BMJ. 2020 Sep 9;370:m3339
pubmed: 32907855
BMJ. 2020 May 22;369:m1985
pubmed: 32444460